-+ 0.00%
-+ 0.00%
-+ 0.00%

Generate Biomedicines Presents Phase 3 Asthma Program for Twice-Yearly GB-0895

PUBT·10/23/2026 18:30:26
Listen to the news
Generate Biomedicines Presents Phase 3 Asthma Program for Twice-Yearly GB-0895
  • Generate Biomedicines is advancing twice-yearly anti-TSLP antibody GB-0895 through Phase 3 trials in severe asthma.
  • SOLAIRIA-1 and SOLAIRIA-2 target full enrollment in the second half of 2027 and first half of 2028.
  • GB-0895 Phase 1b results in moderate-to-severe COPD are expected in the second half of 2026.
  • MMAE neutralizer GB-4362 is in Phase 1 development, with results expected in 2027.
  • A Zealand Pharma platform collaboration expands the pipeline into obesity through two confidential programs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.